Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses ...
The European approval for GSK's depemokimab joins recently announced data on vaccine efficacy and progress on 4-month viral treatments.
5d
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
US$82 Million in Pending Proposals Across Multiple Infectious Disease ProgramsUS$40 Million NIAID Funding Award Supports VXV-01 Development ...
Automation and AI are revolutionizing the pharmaceutical industry, optimizing technical development and enabling faster, more ...
Montreal and Québec City Friday, February 13, 2026, 17:00 Hrs [IST] ...
CNW/ - Aramis Biotechnologies Inc. ("Aramis"), a Canadian company pioneering and a global leader in plant‑based bioproduction ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment -- VK2735 Maintenance Dosing Study Fully Enrolled; Data Expected ...
The journey towards circular high-performance composites begins with one core question: why redesign an already mature class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results